An observational study in Dental Caries and Pulpotomies Primary Teeth, sponsored by Marmara University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 4 Years to 9 Years. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Marmara University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Dental Caries by Marmara University — 3 open to participants now, 4 under way, none of them phase 3. Dental Caries · Marmara University.
Among the 12 studies in Dental Caries by Marmara University, this one is one of 3 that started in 2025, is one of 8 observational ones, and was the 9th registered.
1,176 studies on the registry are indexed under Dental Caries; 209 are open to participants now.
Browse Dental Caries studies →3 of the 12 studies in Dental Caries by Marmara University are open now, in 1 country. Recruiting first, the newest first:
Marmara University · Sites in Turkey
Ages 4–13 · Healthy volunteers
Marmara University · Sites in Turkey
Ages 6–10 · Healthy volunteers
Marmara University
Ages 5–9 · Healthy volunteers
By country, each count listing its studies:
Of the 86 Dental Caries studies recruiting now, 18 (21%) set no upper age limit and 66 (77%) stop at 75 or younger; 60 take children under 18; 53 take healthy volunteers.
This study: 4 Years to 9 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2025.
This study's enrollment of 56 is below the median of 172 across 192 observational studies indexed under Dental Caries.
Median enrollment 65 across the 4 interventional studies, 137 across the 8 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Marmara University is the lead sponsor of 601 studies on the registry; 137 are open to participants now.
1 of the studies in Dental Caries by Marmara University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07548008Marmara UniversityFerric Sulfate and Sodium Hypochlorite Pulpotomies in Vital Primary Teeth | 2027-02-10 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Dental Caries by Marmara University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to compare the clinical and radiographic success of two commonly used pulpotomy agents, ferric sulfate (FS) and sodium hypochlorite (NaOCl), in vital primary molars. Pulpotomy is a widely used vital pulp therapy procedure in pediatric dentistry to preserve primary teeth until their natural exfoliation.
The study will include children aged 4-9 years who previously received pulpotomy treatment using either FS or NaOCl at Marmara University Faculty of Dentistry. No additional treatment will be performed as part of this study. Patients will be followed during routine clinical visits at 6, 12, and 24 months.
Clinical outcomes such as pain, mobility, and infection, as well as radiographic findings including resorption and radiolucency, will be evaluated. The results of this study are expected to provide evidence for the effectiveness of these materials and support clinical decision-making in pediatric dental practice.
The study population consists of children aged 4-9 years who were treated at the Department of Pediatric Dentistry, Marmara University Faculty of Dentistry. These participants had previously undergone pulpotomy treatment in vital primary molars using either ferric sulfate or sodium hypochlorite as part of routine clinical care.
The study includes patients with available clinical records and diagnostic radiographs, and who are followed during routine recall visits at 6, 12, and 24 months. No additional interventions are performed as part of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 4-9 years who received pulpotomy treatment in vital primary molars using 15.5% ferric sulfate as part of routine clinical care.
Children aged 4-9 years who received pulpotomy treatment in vital primary molars using 5% sodium hypochlorite as part of routine clinical care.
Clinical and Radiographic Success Rate of Pulpotomy
The primary outcome is the clinical and radiographic success of pulpotomy-treated primary teeth. Clinical success is defined as the absence of pain, mobility, fistula, abscess, or tenderness to percussion. Radiographic success is defined as the absence of internal or external resorption, periapical or furcal radiolucency, and other pathological findings.
Time frame: 24 months
Clinical Success Rate
Evaluation of clinical success based on absence of pain, mobility, fistula, abscess, and tenderness.
Time frame: 6, 12, and 24 months
Radiographic Success Rate
Evaluation of radiographic success based on absence of pathological findings such as resorption and radiolucency.
Time frame: 6, 12, and 24 months
Plan to share: No — Individual participant data (IPD) will not be shared due to privacy and confidentiality considerations. The study involves pediatric participants, and all data are anonymized and handled in accordance with ethical guidelines and data protection regulations.
Started Aug 2025 (actual). Primary completion is estimated for Feb 2027, 18 months after the start.
Of 48 non-industry observational studies under Dental Caries, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 32. This study's planned 18 months is above that.
Counting every sponsor, half of 49 studies reached it within 12 months; a quarter within 7 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.